Effects of recombinant human erythropoietin on the growth of various human tumor cells

Biotherapy

Volumn 19, Issue 2, 2005, Pages 181-196

  Sugawa, Makoto ^a   Fukui, Hiroyasu ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cancer associated anemia; Cell proliferation; Chemotherapy; Erythropoietin (EPO); Human tumor cell

Indexed keywords

BROXURIDINE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLADDER CANCER; BONE MARROW; BREAST CANCER; CANCER ASSOCIATED ANEMIA; CANCER PATIENT; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; ERYTHROID PRECURSOR CELL; EUROPE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; KIDNEY FAILURE; LARGE INTESTINE CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MITOGENESIS; MYELOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; STOMACH CANCER; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; UNITED STATES; UTERINE CERVIX CANCER;

EID: 17644420642     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Yu, X., Lin, C.Y., Costantini, F., et al: The human erythropoietin receptor gene rescues erythrooiesis and developmental defects in the erythropoietin receptor null mouse. Blood 98(2): 475-477, 2001.
2. Lappin, T.R., Maxwell, A.P. and Johnston, P.G.: EPO's alter ego: erythropoietin has multiple actions. Stem Cells 20(6): 485-492, 2002. (review)
3. Lappin, T.: The cellular biology of erythropoietin receptors. Oncologist 8(Suppl. 1): 15-18, 2003. (review)
4. Batra, S., Perelman, N., Luck, L.R., et al.: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab. Invest. 83(10): 1477-1487, 2003.
5. Acs, G., Zhang, P.J., McGrath, C.M., et al.: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am. J. Pathol. 162(6): 1789-1806, 2003.
6. Westenfelder, C. and Baranowski, R.L.: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58 (2): 647-657, 2000.
7. Westphal, G., Niederberger, E., Slum, C., et al.: Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 88 (2): 150-159, 2002.
8. Yasuda, Y., Fujita, Y., Masuda, S., et al.: Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23(11): 1797-1805, 2002.
9. Arcasoy, M.O., Amin, K., Karayal, A.F., et al.: Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 82(7): 911-918, 2002.
10. Ribatti, D., Vacca, A., Roccaro, A.M., et al.: Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest. 33(10): 891-896, 2003. (review)
11. Yasuda, Y., Fujita, Y., Matsuo, T., et al.: Erythropoietin regulates tumour growth of humanmolalignancies. Carcinogenesis 24(6): 1021-1029, 2003.
12. Bahlmann, F.H., DeGroot, K., Duckert, T., et al.: Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64(5): 1648-1652, 2003.
13. Okuno, Y., Takahashi, T., Suzuki, A., et al: Expression of the erythropoietin receptor on a human myeloma cell line. Biochem. Biophys. Res. Commun. 170(3): 1128-1134, 1990.
14. Berdel, W.E., Oberberg, D. and Reufi, B.: Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann. Hematol. 63(1): 5-8, 1991.
15. Takeshita, A., Shinjo, K., Naito, K., et al.: Erythropoietin receptor in myelodysplastic syndrome and leukemia. Leuk. Lymphoma. 43(2): 261-264, 2002. (review)
16. Acs, G., Acs, P., Beckwith, S.M., et al.: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61 (9): 3561-3565, 2001.
17. Henke, M., Laszig, R., Rube, C., et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362(9392): 1255-1260, 2003.
18. Leyland-Jones, B.: BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4(8): 459-460, 2003.
19. Luksenburg, H., Weir, A. and Wager, R. (Oncologic Drugs Advisory Committee): Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. And Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy. FDA Briefing Document. May 4, 2004.
20. Littlewood, T.J., Bajetta, E., Nortier, J.W., et al.: Epoetin Alfa Study Group.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double - blind, placebo - controlled trial. J. Clin. Oncol. 19(11): 2865-2874, 2001.
21. Vansteenkiste, J., Pirker, R., Massuti, B., et al.: Aranesp 980297 Study Group.: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl. Cancer Inst. 94(16): 1211-1220, 2002.
22. Miyazaki, Y., Kuriyama, K., Higuchi, M., et al.: Establishment and characterization of a new erythropoietin - dependent acute myeloid leukemia cell line, AS-E. Leukemia 11(11): 1941-1949, 1997.
23. Soto, A.M. and Sonnenschein, C.: The role of estrogens on the proliferation of human breast tumor cells (MCF-7). J. Steroid Biochem. Mol. Biol. 23(1): 87-94, 1985.
24. Payne, J., Jones, C., Lakhani, S., et al.: Kortenkamp A. Improving the reproducibility of the MCF-7 cell proliferation assay for the detection of xenoestrogens. Sci. Total Environ. 248(1): 51-62, 2000.
25. Hur, J., Chesnes, J., Coser, K.R., et al.: The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc. Natl. Acad. Sci. USA 101(8): 2351-2356, 2004.
26. Coser, K.R., Chesnes, J., Hur, J., et al.: Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc. Natl. Acad. Sci. USA 100(24): 13994-13999, 2003.
27. Arcasoy, M.O., Jiang, X. and Haroon, Z.A.: Expression of erythropoietin receptor splice variants in human cancer. Biochem. Biophys. Res. Commun. 307(4): 999-1007, 2003.
28. Westenfelder, C., Biddle, D.L. and Baranowski, R.L.: Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 55(3): 808-820, 1999.
29. Anagnostou, A., Liu, Z., Steiner, M., et al.: Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 91(9): 3974-3978, 1994.
30. Anagnostou, A., Lee, E.S. and Kessimian, N.: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 87(15): 5978-5982, 1990.
31. Ribatti, D., Presta, M., Vacca, A., et al.: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93: 2627-2636, 1999.
32. Ashley, R.A., Dubuque, S.H., Dvorak, B., et al.: Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr. Res. 51(4): 472-478, 2002.
33. Ribatti, D., Marzullo, A., Nico, B., et al.: Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 42(3): 246-250, 2003.
34. Wollman, Y., Westphal, G., Blum, M., et al.: The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci. 59(4): 315-322, 1996.
35. Mittelman, M., Neumann, D., Peled, A., et al.: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc. Natl. Acad. Sci. USA 98(9): 5181-5186, 2001.